financetom
OLK
financetom
/
Healthcare
/
OLK
All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities
Olink Holding AB (publ)OLK
USD
- At close
USD
- Until the end
The complete list of US stocks
1D
5D
1M
1Y
5Y
MAX
Overview >
% Change
Description >

Olink Holding AB (publ) provides various products and services for the academic, government, biopharmaceutical, biotechnology, service provider, and other institutions that focuses on life science research.

The company's products include Olink Explore for cardiovascular and metabolic, oncology, neurology, or inflammation diseases; Olink Target product line; Olink Flex, a low-plex applications and use-cases; and Olink Focus product line that consists of custom developed solutions for customers that has identified various proteins of interest or a protein signature to focus on.

Its products also comprise Olink Signature Q100, a qPCR readout platform; Olink Analysis services comprising study design and consultation, sample preparation and assay execution, and data processing and QC; and bioinformatics services.

In addition, the company provides Olink normalized protein expression (NPX) Manager, a purpose-built software that enable users to import data, perform data analysis including visualizations, and statistical modelling; and Olink Insight, a cloud platform for Olink community to accelerate proteomics.

It sells its products and services through its own direct sales force in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.

The company was formerly known as Knilo HoldCo AB and changed its name to Olink Holding AB (publ) in January 2021.

The company was founded in 2004 and is headquartered in Uppsala, Sweden.

Latest News >
Science Applications International Fiscal Q1 Adjusted Earnings, Revenue Decline; Fiscal 2025 Guidance Reiterated
Science Applications International Fiscal Q1 Adjusted Earnings, Revenue Decline; Fiscal 2025 Guidance Reiterated
Jun 3, 2024
07:40 AM EDT, 06/03/2024 (MT Newswires) -- Science Applications International ( SAIC ) reported fiscal Q1 adjusted earnings Monday of $1.92 per diluted share, down from $2.14 a year earlier. Analysts polled by Capital IQ expected $1.92. Revenue for the fiscal quarter ended May 3 was $1.85 billion, down from $2.03 billion a year earlier. Analysts surveyed by Capital IQ...
Update: Generation Mining Applauds International Energy Forum Report Outlining EV Copper Hurdles
Update: Generation Mining Applauds International Energy Forum Report Outlining EV Copper Hurdles
Jun 3, 2024
07:37 AM EDT, 06/03/2024 (MT Newswires) -- Generation Mining ( GENMF ) on Monday cheered a recent report by the International Energy Forum outlining rising global demand for copper amid the energy transition. The report, titled Copper Mining and Vehicle Electrification, found that the world will not be able to produce enough copper to transition to 100% electric vehicle production...
Market Chatter: Blackstone Considering Sale of Alinamin Pharmaceutical
Market Chatter: Blackstone Considering Sale of Alinamin Pharmaceutical
Jun 3, 2024
07:32 AM EDT, 06/03/2024 (MT Newswires) -- Blackstone (BX) is exploring the sale of Alinamin Pharmaceutical Co., a Japanese consumer healthcare firm previously owned by Takeda Pharmaceutical Co. for around 300 billion yen ($1.9 billion), Bloomberg reported on Monday, citing people familiar with the situation. Interest in Alinamin has been expressed by investment firms such as CVC Capital Partners Plc,...
Structure Therapeutics' obesity drug meets main goal in mid-stage study
Structure Therapeutics' obesity drug meets main goal in mid-stage study
Jun 3, 2024
June 3 (Reuters) - Structure Therapeutics ( GPCR ) said on Monday its obesity drug candidate met the main goal in a mid-stage study. (Reporting by Mariam Sunny in Bengaluru; Editing by Devika Syamnath) ...
Copyright 2023-2025 - www.financetom.com All Rights Reserved